DK1743027T3 - Mutantpneumolysinproteiner - Google Patents

Mutantpneumolysinproteiner

Info

Publication number
DK1743027T3
DK1743027T3 DK05742528.2T DK05742528T DK1743027T3 DK 1743027 T3 DK1743027 T3 DK 1743027T3 DK 05742528 T DK05742528 T DK 05742528T DK 1743027 T3 DK1743027 T3 DK 1743027T3
Authority
DK
Denmark
Prior art keywords
mutant pneumolysin
pneumolysin proteins
proteins
mutant
pneumolysin
Prior art date
Application number
DK05742528.2T
Other languages
English (en)
Inventor
Lea-Ann Kirkham
Timothy John Mitchell
Original Assignee
Univ Glasgow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Glasgow filed Critical Univ Glasgow
Application granted granted Critical
Publication of DK1743027T3 publication Critical patent/DK1743027T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
DK05742528.2T 2004-05-07 2005-05-09 Mutantpneumolysinproteiner DK1743027T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56941504P 2004-05-07 2004-05-07
GBGB0410220.8A GB0410220D0 (en) 2004-05-07 2004-05-07 Mutant pneumolysin proteins
PCT/GB2005/001792 WO2005108580A1 (en) 2004-05-07 2005-05-09 Mutant pneumolysin proteins

Publications (1)

Publication Number Publication Date
DK1743027T3 true DK1743027T3 (da) 2013-09-30

Family

ID=32482854

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05742528.2T DK1743027T3 (da) 2004-05-07 2005-05-09 Mutantpneumolysinproteiner

Country Status (15)

Country Link
US (1) US7820789B2 (da)
EP (1) EP1743027B1 (da)
JP (1) JP4848552B2 (da)
KR (1) KR101191591B1 (da)
CN (1) CN101018863B (da)
AU (1) AU2005240835B2 (da)
CA (1) CA2566344C (da)
DK (1) DK1743027T3 (da)
ES (1) ES2427978T3 (da)
GB (1) GB0410220D0 (da)
IL (2) IL178885A (da)
PL (1) PL1743027T3 (da)
PT (1) PT1743027E (da)
SI (1) SI1743027T1 (da)
WO (1) WO2005108580A1 (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US9370557B2 (en) * 2006-06-15 2016-06-21 The University Court Of The University Of Glasgow Adjuvant compounds
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
CA2683748C (en) * 2007-04-13 2016-02-16 The Board Of Regents Of The University Of Oklahoma Mutants of cholesterol-dependent cytolysins and uses thereof
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
RU2498994C2 (ru) * 2007-12-21 2013-11-20 Новартис Аг Мутантные формы стрептолизина о
US9125863B2 (en) * 2008-05-22 2015-09-08 Children's Medical Center Corporation Synergistic immunogenic fusion protein-polysaccharide conjugate
CA2748149C (en) * 2008-12-24 2018-03-06 Netherlands Vaccine Institute Modified steptococcus pneumonia pneumolysin (ply) polypeptides
WO2010109324A1 (en) 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
RU2536248C2 (ru) * 2009-04-30 2014-12-20 Коули Фармасьютикал Груп, Инк. Пневмококковая вакцина и ее применения
EP2475385A1 (en) 2009-09-10 2012-07-18 Novartis AG Combination vaccines against respiratory tract diseases
CN102939105B (zh) * 2009-12-22 2016-11-16 赛诺菲巴斯德有限公司 免疫原性组合物和相关的方法
BR112012018343A2 (pt) * 2009-12-22 2017-06-27 Sanofi Pasteur Ltd "composições imunogênicas"
WO2012025873A2 (en) 2010-08-23 2012-03-01 Wyeth Llc STABLE FORMULATIONS OF NEISSERIA MENINGITIDIS rLP2086 ANTIGENS
JP5976652B2 (ja) 2010-09-10 2016-08-24 ワイス・エルエルシー 髄膜炎菌ｏｒｆ２０８６抗原の非脂質化変異体
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
WO2012134975A1 (en) 2011-03-28 2012-10-04 St. Jude Children's Research Hospital Methods and compositions employing immunogenic fusion proteins
EP2694667B1 (en) 2011-04-08 2016-12-07 Baystate Medical Center, Inc. Methods, compositions and kits for assaying mitochondrial function
CN115887627A (zh) * 2011-04-21 2023-04-04 洛克菲勒大学 用于革兰氏阳性菌检测和治疗的链球菌属细菌噬菌体溶素
ES2864765T3 (es) 2011-05-11 2021-10-14 Childrens Medical Center Proteína de unión a biotina modificada, proteínas de fusión de la misma y aplicaciones
CN103533953A (zh) 2011-05-17 2014-01-22 葛兰素史密丝克莱恩生物有限公司 针对肺炎链球菌的疫苗
ITMI20111182A1 (it) 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
WO2013131983A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP3485906A1 (en) 2012-03-09 2019-05-22 Pfizer Inc Neisseria meningitidis compositions and methods thereof
AU2014214844B2 (en) 2013-02-07 2017-12-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
US11207396B2 (en) 2013-05-17 2021-12-28 The Board Of Regents Of The University Of Texas System Immunization to protect against adverse cardiac events relating to pneumococcal infection
KR20180099912A (ko) 2013-09-08 2018-09-05 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
CN103936842B (zh) * 2014-04-30 2016-03-23 重庆医科大学 肺炎链球菌溶血素突变体及其作为粘膜免疫佐剂的应用
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
US10562941B2 (en) 2014-11-21 2020-02-18 The Board Of Regents Of The University Of Oklahoma Pneumolysin mutants and methods of use thereof
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
SG10202111092UA (en) 2017-01-31 2021-11-29 Pfizer Neisseria meningitidis compositions and methods thereof
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
AU2018243910A1 (en) 2017-03-28 2019-11-14 The Children's Medical Center Corporation A multiple antigen presenting system (MAPS)-based staphylococcus aureus vaccine, immunogenic composition, and uses thereof
US11612647B2 (en) 2017-06-23 2023-03-28 University Of Maryland, Baltimore Immunogenic compositions
JP2021535921A (ja) 2018-09-12 2021-12-23 アフィニバックス、インコーポレイテッド 多価肺炎球菌ワクチン
EP4317182A1 (en) * 2021-03-22 2024-02-07 Starmab Biologics (Suzhou) Co., Ltd Antigen-binding protein targeting streptococcus pneumoniae hemolysin protein and use thereof
CN113264999B (zh) * 2021-04-29 2023-02-28 星济生物(苏州)有限公司 中和肺炎链球菌溶血素蛋白的抗原结合蛋白及其用途
WO2023039223A1 (en) 2021-09-09 2023-03-16 Affinivax, Inc. Multivalent pneumococcal vaccines
WO2023092090A1 (en) 2021-11-18 2023-05-25 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US6716432B1 (en) * 1988-12-16 2004-04-06 James Cleland Paton Pneumolysin mutants and pneumococcal vaccines made therefrom
CA2005704C (en) * 1988-12-16 2003-02-11 James C. Paton Pneumolysin mutants and pneumococcal vaccines made therefrom
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
JPH07507854A (ja) 1991-12-23 1995-08-31 ツォッヒェ，ミヒャエル 油除去装置を備えたエンジン
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
KR20070108418A (ko) 1996-10-23 2007-11-09 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 면역 치료법 및 개량 백신
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6764686B2 (en) * 1997-07-21 2004-07-20 Baxter International Inc. Modified immunogenic pneumolysin compositions as vaccines
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
KR100743894B1 (ko) 1998-02-27 2007-07-30 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 백신, 면역치료제 및 그의 이용 방법
CA2344740C (en) 1998-09-30 2011-11-22 American Cyanamid Company Mutant cholera holotoxin as an adjuvant
WO2002098369A2 (en) 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
ATE451386T1 (de) 2001-06-07 2009-12-15 Wyeth Corp Mutantenformen von cholera holotoxin als adjuvans
JP4764830B2 (ja) 2003-12-17 2011-09-07 ワイス・エルエルシー 免疫原性ペプチド担体コンジュゲートおよびその生産法

Also Published As

Publication number Publication date
CN101018863A (zh) 2007-08-15
AU2005240835B2 (en) 2011-12-01
WO2005108580A1 (en) 2005-11-17
PL1743027T3 (pl) 2013-11-29
ES2427978T3 (es) 2013-11-05
CA2566344A1 (en) 2005-11-17
IL178885A0 (en) 2007-03-08
KR20070073602A (ko) 2007-07-10
KR101191591B1 (ko) 2012-10-15
US20080112964A1 (en) 2008-05-15
IL203479A (en) 2013-04-30
GB0410220D0 (en) 2004-06-09
CN101018863B (zh) 2012-01-04
JP2008505617A (ja) 2008-02-28
SI1743027T1 (sl) 2013-10-30
JP4848552B2 (ja) 2011-12-28
EP1743027B1 (en) 2013-07-10
US7820789B2 (en) 2010-10-26
IL178885A (en) 2011-11-30
AU2005240835A1 (en) 2005-11-17
EP1743027A1 (en) 2007-01-17
CA2566344C (en) 2015-07-07
PT1743027E (pt) 2013-10-08

Similar Documents

Publication Publication Date Title
DK1743027T3 (da) Mutantpneumolysinproteiner
DE50310628D1 (de) Erfahren
DK1699821T3 (da) Fc-ERYTHROPOIETIN-FUSIONSPROTEIN MED FORBEDREDE FARMAKOKINETIKKER
DE602005021602D1 (de) Neigungsverstellvorrichtung
DK1804871T3 (da) Forbedret mellemstykke
DE602005021745D1 (de) Neigungsverstellvorrichtung
ITMI20041571A1 (it) Perfluoroelastomeri
DE602005023894D1 (de) Rücklehnvorrichtung
DK1809660T3 (da) Thymus-specifikt protein
ATE521769T1 (de) Beschlag
ES1064684Y (es) Tapizado
GB0423974D0 (en) Proteins
DE60322439D1 (de) Anschlussstück
ATA13202003A (de) Sitzmöbel
NO20040521A (no) Proteinutskiller
GB0401882D0 (en) Protein
SE0400209D0 (sv) Novel methods
ES1060725Y (es) Reclinalibros
ES1057547Y (es) Roldana mejorada
UA10445S (uk) Подушка
ES1057042Y (es) Conjunto anillo-pendientes
SE0400497D0 (sv) Artikulator
FR2858310B1 (fr) Licol ameliore
GB0405885D0 (en) Proteins
GB0405643D0 (en) Proteins